Trastuzumab and pertuzumab is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Fudan University (1) and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1). Registered phases: Phase 2 and Phase 3. Conditions studied include Advanced HER2-positive Breast Cancer; Early-stage Breast Cancer; HER2-positive Breast Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab (ClinicalTrials.gov ↗) Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab |
Phase 3 | Recruiting |
| NCT07581795 | Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer (ClinicalTrials.gov ↗) Advanced HER2-positive Breast Cancer |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced HER2-positive Breast Cancer | 1 |
| Early-stage Breast Cancer | 1 |
| HER2-positive Breast Cancer | 1 |
| Adjuvant Treatment After Trastuzumab | 1 |
| RCB Classification 1-2 | 1 |
| Lead sponsor | Trials |
|---|---|
| Fudan University | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| Register | Trastuzumab and pertuzumab trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trastuzumab and pertuzumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trastuzumab and pertuzumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.